Richard Larson to Leukemia, Lymphocytic, Chronic, B-Cell
This is a "connection" page, showing publications Richard Larson has written about Leukemia, Lymphocytic, Chronic, B-Cell.
Connection Strength
3.697
-
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018 07 24; 2(14):1705-1718.
Score: 0.524
-
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10; 28(29):4500-6.
Score: 0.302
-
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct; 50(10):1589-96.
Score: 0.285
-
Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2007 Apr; 48(4):829-32.
Score: 0.239
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005 Jan 01; 105(1):49-53.
Score: 0.196
-
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024 04 18; 143(16):1616-1627.
Score: 0.195
-
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861.
Score: 0.161
-
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.
Score: 0.157
-
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528.
Score: 0.134
-
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. Leuk Lymphoma. 2015; 56(11):3031-7.
Score: 0.104
-
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500.
Score: 0.103
-
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia. 2015 May; 29(5):1210-3.
Score: 0.102
-
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma. 2013 Dec; 54(12):2654-9.
Score: 0.091
-
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013 Feb 01; 31(4):440-7.
Score: 0.089
-
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma. 2013 Feb; 54(2):252-4.
Score: 0.087
-
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma. 2012 Sep; 53(9):1743-8.
Score: 0.086
-
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10; 30(20):2483-91.
Score: 0.085
-
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011 Sep 29; 118(13):3525-7.
Score: 0.081
-
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011 Apr 01; 29(10):1349-55.
Score: 0.078
-
Chronic lymphocytic leukemia masquerading as uveitis. Retina. 2007 Nov-Dec; 27(9):1311-2.
Score: 0.062
-
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007 Mar 01; 25(7):799-804.
Score: 0.059
-
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007 Mar 01; 25(7):793-8.
Score: 0.059
-
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20; 24(3):437-43.
Score: 0.055
-
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7.
Score: 0.054
-
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005 Jun 01; 11(11):4176-81.
Score: 0.053
-
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 2003 Feb; 17(2):323-7.
Score: 0.045
-
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002 Sep 15; 20(18):3878-84.
Score: 0.044
-
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002 Jul; 50(1):37-45.
Score: 0.043
-
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001 Aug 15; 19(16):3611-21.
Score: 0.041
-
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14; 343(24):1750-7.
Score: 0.039
-
Listeriosis after 2-chlorodeoxyadenosine treatment. N Engl J Med. 1993 Mar 18; 328(11):813-4.
Score: 0.023
-
Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. Blood. 1992 Apr 01; 79(7):1796-801.
Score: 0.021